Target Details
| UniProt AC | P23458 |
|---|---|
| Gene Symbol | JAK1 |
| Protein Name | Tyrosine-protein kinase JAK1 |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF18379 (FERM_F1) PF18377 (FERM_F2) PF17887 (Jak1_Phl) PF07714 (PK_Tyr_Ser-Thr) PF21990 (SH2_1) |
Summary
- Multi-target molecules 8,920
- Clinical molecules 14
- Avg pChEMBL 8.26
KEGG Pathways (28)
- Coronavirus disease - COVID-19
- EGFR tyrosine kinase inhibitor resistance
- Epstein-Barr virus infection
- Hepatitis B
- Hepatitis C
- Herpes simplex virus 1 infection
- Human T-cell leukemia virus 1 infection
- Human cytomegalovirus infection
- Human papillomavirus infection
- Influenza A
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Leishmaniasis
- Measles
- NOD-like receptor signaling pathway
- Necroptosis
- Osteoclast differentiation
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Pathways in cancer
- Signaling pathways regulating pluripotency of stem cells
- Th1 and Th2 cell differentiation
- Th17 cell differentiation
- Toll-like receptor signaling pathway
- Toxoplasmosis
- Tuberculosis
- Viral carcinogenesis
Associated Diseases (1)
Active Molecules (8,920)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
IKSRDHMMQOCRHN
|
10.0 | Ki | 4 | — | |
IKSRDHMMQOCRHN
|
10.0 | Ki | 2 | — | |
ILTMPNUQSMRDOS
|
10.0 | IC50 | 4 | — | |
JEQHZFJUEIXQQT
|
10.0 | IC50 | 4 | — | |
JILWGJUHCXJGAA
|
10.0 | IC50 | 2 | — | |
JKESNMWWWWZHEN
|
10.0 | IC50 | 4 | — | |
JLTOWQJUNJJFGB
|
10.0 | IC50 | 2 | — | |
JOZPVZZAGAGVLD
|
10.0 | IC50 | 2 | — | |
KAHARENCCCTWSQ
|
10.0 | Ki | 4 | — | |
KAVVKRQBEAWLIE
|
10.0 | Ki | 4 | — | |
KEUWNLFXTTVHAQ
|
10.0 | IC50 | 2 | — | |
KYZUAOWEMYTNAI
|
10.0 | IC50 | 2 | — | |
KZDYCWOHUSQCAJ
|
10.0 | IC50 | 2 | — | |
MHIGHFSHEYTZFT
|
10.0 | IC50 | 2 | — | |
MOZBSVJPDSKZMY
|
10.0 | IC50 | 4 | — | |
MXZNRXIGJIAJNT
|
10.0 | IC50 | 4 | — | |
NAXUVOPYFVMTNB
|
10.0 | IC50 | 4 | — | |
NPIRZUMAGGQJIG
|
10.0 | IC50 | 2 | — | |
OGCZPYZSIANOCF
|
10.0 | IC50 | 2 | — | |
PCIVQDNLJCQJCG
|
10.0 | IC50 | 4 | — | |
PSGBFSWASSKHAE
|
10.0 | IC50 | 4 | — | |
PTYZWRDJQNYYOD
|
10.0 | Ki | 2 | — | |
QCGBDTSLOLLHEJ
|
10.0 | Ki | 4 | — | |
QCGBDTSLOLLHEJ
|
10.0 | Ki | 4 | — | |
RORMJCXVRLHBIE
|
10.0 | IC50 | 4 | — | |
RVTCNVYHXAOTAQ
|
10.0 | IC50 | 2 | — | |
SKLWZKYYWLLLGE
|
10.0 | IC50 | 2 | — | |
SMDPPQPEXWEBHM
|
10.0 | IC50 | 4 | — | |
TWNHDYRZRRWJBV
|
10.0 | IC50 | 2 | — | |
TXIKSAFNAMPZNK
|
10.0 | IC50 | 2 | — | |
UOSGIRBXSBYVHS
|
10.0 | IC50 | 4 | — | |
UQIMQIIIPITHKG
|
10.0 | IC50 | 2 | — | |
UVKCEETVNJEFST
|
10.0 | IC50 | 2 | — | |
UYIXMUYRGIUKNR
|
10.0 | IC50 | 2 | — | |
VCNGELAFKHCXSO
|
10.0 | IC50 | 4 | — | |
VXVPFZWBCFUGPX
|
10.0 | IC50 | 2 | — | |
WFBYDUIMMVFPLN
|
10.0 | IC50 | 2 | — | |
WIICDYUXOKRMJM
|
10.0 | Ki | 2 | — | |
WIICDYUXOKRMJM
|
10.0 | Ki | 4 | — | |
WJAGYFYDSQXEDC
|
10.0 | Ki | 2 | — | |
WKMLRCUOFWMMMO
|
10.0 | IC50 | 4 | — | |
WNVSABGLXFTXRN
|
10.0 | Ki | 2 | — | |
WPFVOGVFFHKWNS
|
10.0 | IC50 | 2 | — | |
WVIMYKAIQXCCSA
|
10.0 | IC50 | 2 | — | |
XGPGNLBIUUNYJN
|
10.0 | IC50 | 2 | — | |
YKTNKWVDICOPMZ
|
10.0 | IC50 | 2 | — | |
YNCPHYIVCGFBLQ
|
10.0 | IC50 | 2 | — | |
YPPVVRMVBMJTQI
|
10.0 | IC50 | 2 | — | |
ZFGRPZIMBQPZJH
|
10.0 | IC50 | 4 | — | |
ZHNINLCJCQXCPY
|
10.0 | IC50 | 2 | — |